Tetrahydropapaveroline in Parkinson's Disease and Alcoholism: A Look Back in Honor of Merton Sandler

Author： Collins M.A.  

Publisher： Elsevier

ISSN： 0161-813X

Source： Neurotoxicology, Vol.25, Iss.1, 2004-01, pp. : 117-120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Reply: a new look at the pathogenesis of Parkinson's disease

By Przedborski S.   Vila M.   Jackson-Lewis V.   Dawson T.M.  

Trends in Pharmacological Sciences, Vol. 21, Iss. 5, 2000-05 ,pp. : 165-165

Elsevier

Access to resources Recommend Favorite

Disease Modification in Parkinson's Disease

By Henchcliffe Claire  

Drugs & Aging, Vol. 28, Iss. 8, 2011-08 ,pp. : 605-615

Adis International

Access to resources Recommend Favorite

Rivastigmine in Parkinson's disease dementia

By Chitnis Shilpa   Rao Jayaraman  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 8, 2009-08 ,pp. : 941-955

Informa Healthcare

Access to resources Recommend Favorite

Nicotinic receptors and Parkinson's disease

By Quik M.   Jeyarasasingam G.  

European Journal of Pharmacology, Vol. 393, Iss. 1, 2000-03 ,pp. : 223-230

Elsevier

Access to resources Recommend Favorite

Rivastigmine: In Parkinson's Disease Dementia

By Siddiqui M. Asif A.   Wagstaff Antona J.  

CNS Drugs, Vol. 20, Iss. 9, 2006-01 ,pp. : 739-747

Adis International

Access to resources Recommend Favorite